Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2009 Jun 18;360(25):2683-5.
doi: 10.1056/NEJMc0808481.

B-cell-depleting induction therapy and acute cellular rejection

Menna R Clatworthy, Christopher J E Watson, Gemma Plotnek, Vicky Bardsley, Afzal N Chaudhry, J Andrew Bradley, Kenneth G C Smith
Randomized Controlled Trial

B-cell-depleting induction therapy and acute cellular rejection

Menna R Clatworthy et al. N Engl J Med. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1. Increased Rate of Acute Rejection in Rituximab-Treated Patients
Kaplan–Meier curves are shown for rejection-free survival at 1 year in patients who received rituximab as induction therapy, as compared with those who received daclizumab. The P value for the difference is based on a log-rank test.
See this image and copyright information in PMC

Comment in

References

    1. Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing–remitting multiple sclerosis. N Engl J Med. 2008;358:676–88. - PubMed
    1. Zarkhin V, Li L, Sarwal M. “To B or not to B?” B-cells and graft rejection. Transplantation. 2008;85:1705–14. - PubMed
    1. Vincenti F, Kirkman R, Light S, et al. Interleukin-2–receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Engl J Med. 1998;338:161–5. - PubMed
    1. Agarwal A, Vieira CA, Book BK, Sidner RA, Fineberg NS, Pescovitz MD. Rituximab, anti-CD20, induces in vivo cytokine release but does not impair ex vivo T-cell responses. Am J Transplant. 2004;4:1357–60. - PubMed
    1. Matsushita T, Yanaba K, Bouaziz JD, Fujimoto M, Tedder TF. Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J Clin Invest. 2008;118:3420–30. - PMC - PubMed